Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

Author:

Sepúlveda Maria1,Aldea Marta2,Escudero Domingo1,Llufriu Sara1,Arrambide Georgina3,Otero-Romero Susana4,Sastre-Garriga J3,Romero-Pinel Lucía5,Martínez-Yélamos Sergio5,Sola-Valls N1,Armangué Thais6,Sotoca Javier7,Escartín Antonio7,Robles-Cedeño René8,Ramió-Torrentà Lluís8,Presas-Rodríguez Silvia9,Ramo-Tello Cristina9,Munteis Elvira10,Pelayo Raúl11,Gubieras Laura12,Brieva Luis13,Ortiz Nicolau14,Hervás Mariona15,Mañé-Martínez Maria Alba16,Cano Antonio17,Vela Emili18,Tintoré Mar3,Blanco Yolanda1,Montalban Xavier19,Graus Francesc1,Saiz Albert1

Affiliation:

1. Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic of Barcelona and Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

2. Department of Preventive Medicine and Epidemiology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain

3. Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

4. Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

5. Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, Barcelona, Spain

6. Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic of Barcelona and Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain/Pediatric Neuroimmunology and Neuroinfections Unit, Hospital Sant Joan de Déu Barcelona, University of Barcelona, Spain/Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain

7. Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

8. Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Doctor Josep Trueta University Hospital, Girona, Spain/ Santa Caterina Hospital, Girona, Spain/Biomedical Research Institute (IDIBGI), Girona, Spain/Medical Sciences Department, University of Girona, Girona, Spain

9. Multiple Sclerosis Unit, Neuroscience Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

10. Multiple Sclerosis Unit, Neurology Department, Parc de Salut Mar, Barcelona, Spain

11. Institut Guttmann, Barcelona, Spain

12. Multiple Sclerosis Unit, Neurology Department, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain

13. Multiple Sclerosis Unit, Neurology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain

14. Neurology Department, Hospital Universitari Sant Joan de Reus, Tarragona, Spain

15. Multiple Sclerosis Unit, Neurology Department, Hospital Parc Taulí de Sabadell, Barcelona, Spain

16. Neurology Department, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain

17. Neurology Department, Hospital de Mataró, Barcelona, Spain

18. Unit of Information and Knowledge, Catalan Health Service, Barcelona, Spain

19. Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Division of Neurology, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada

Abstract

Background: Population-based studies on neuromyelitis optica spectrum disorders (NMOSD) are limited, and it is unclear whether the rates have changed with the implementation of the new 2015 criteria. Objectives: To estimate the incidence and prevalence of NMOSD in Catalonia (Spain), using both the 2006 and the 2015 criteria. Methods: In this clinic-based retrospective study, patients diagnosed with NMOSD between 2006 and 2015 were identified using multiple sources, including direct contact to all Catalan hospitals, identification of cases through the Catalan Health Surveillance System, and registry of antibodies to aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) in a reference laboratory. The incidence rate was calculated for the period 1 January 2006–1 January 2016 and prevalence for the date 1 January 2016. Results: We identified 74 patients (by the 2015 criteria). Most patients were Caucasian (81%), and female (76%) with a median age at disease onset of 42 years (range, 10–76 years). In total, 54 (73%) patients were positive for AQP4-IgG, 11 (15%) double-seronegative, and 9 (12%) MOG-IgG-positive. Rates of incidence and prevalence (0.63/1,000,000 person-years and 0.89/100,000, respectively) were 1.5-fold higher than those reported by the 2006 criteria. Lowest rates were seen in children and elder people and highest in women and middle-aged people (40–59 years). The female predominance was lost in incident AQP4-IgG-seronegative children and AQP4-IgG-positive elder people. MOG-IgG and double-seronegativity contributed similarly but did not influence the long-term outcome. Conclusion: The new criteria increase the estimates, but NMOSD remains as a rare disease. The differences in age- and sex-specific estimates highlight the importance of the serologic classification.

Funder

Instituto de salud Carlos III

Departament d'Innovaci�, Universitats i Empresa, Generalitat de Catalunya

Publisher

SAGE Publications

Subject

Clinical Neurology,Neurology

Cited by 83 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3